Science: Breaking through the limitations of in-tumor drug use Two studies have found innovative STING astrologists.

The signaling path, known as STING, activates the production of antibody delivery cells and inflammatory cytokines, which promotes T-cell activation and collection.
a number of biopharmaceutical companies are developing STING astrologists to test their effectiveness as monopharmaceuticals and in association with immunochemical checkpoint inhibitors to control tumor growth.
, however, STING astrologists developed based on cyclic secondary nucleotides (CDNs) need to be given by intra-tumor injection because of their low metabolic stability.
this method of drug preparation has many limitations on the use of STING astrists.
, two different teams published in the journal Science found that non-nucleoside small molecule STING agonists, which are stable, can be given systemically by oral or injection in animal models, and exhibit encouraging anti-cancer activity.
journal Science also contributed to the study.
two studies, two scientific teams developed STING small molecule agitants called SR-717 and MSA-2 using high-volume screening.
both of these agitants bind to STING proteins to fix the protein composition of STING in a fixed "off" state.
in introphy cell culture and mouse models, they were able to exhibit inflammatory cytokines such as interferon beta and IL-6, promote the activation of CD8-positive T cells, and reduce tumor volume.
Photo Source: Resources 1) And MSA-2, developed by a research team at Mercedon (MSD), can only be combined with STING if a djumer is formed, and the acidic conditions of the tumor micro-environment are more conducive to the co-1ation of MSA-2.
means that oral MSA-2, although systemic, has potential tumor specificity, further improving its safety and tolerance.
with PD-1 inhibitors, it can further improve the survival of animals in mouse tumor models.
Photo Source: References: Because STING proteins are present in healthy cells at the same time, one of the challenges that systemic stingors need to address is how to stimulate anti-tumor immune responses without leading to excessive inflammatory reactions in healthy cells.
, published in the journal Science, said the two studies show that specific molecular characteristics of STING astrologists can affect the balance between in-tumor and systemic activity.
if these agitants can be further optimized, they have the potential to revolutionize the field of immunotherapy.
References: ( 1 ) Gajewski and Higgs, (2020). Immunotherapy with a sting. Science, DOI: 10.1126/science.abc6622. Chin et al, (2020). Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic. Science, 10.1126/science.abb4255 ( 3 ) Pan et al, (2020). An orally available non-nucleotide STING agonist with antitumor activity. Science,